Chandrikha Chandrasekharan, MBBS
Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Clinical Associate Professor, Department of Cancer Medicine, Division of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2007 | Government Kilpauk Medical College, Chennai, IN, MBBS |
Postgraduate Training
| 2015-2016 | Advanced GI Medical Oncology, Mayo Clinic, Rochester, Minnesota |
| 2013-2015 | Medical Oncology Fellowship, Louisiana State University, Shreveport, Louisiana |
| 2012-2013 | Hospice and Palliative Medicine Fellowship, Mayo Clinic, Rochester, Minnesota |
| 2009-2012 | Internal Medicine Residency, University Of Florida College of Medicine, Jacksonville, Florida |
Licenses & Certifications
| 2016 | Board Certified in Hospice and Palliative Medicine |
| 2015 | Board Certification Medical Oncology |
| 2012 | ABIM Medical |
| null | Certified Medical Professional - Tamil Nadu (India) Medical Council |
| null | ECFMG Certified |
Experience & Service
Faculty Academic Appointments
Adjunct Clinical Associate Professor, University of Iowa, 2024 - 2025
Clinical Associate Professor, University of Iowa, 2022 - 2024
Principle Investigator, Alliance for Clinical Trails in Oncology, University of Iowa, 2022 - 2024
Gastrointestinal Oncology Multidisciplinary Group Co Leader, University of Iowa, 2022 - 2024
Principle Investigator, Alliance for Clinical Trails in Oncology, Iowa City, 2018 - 2022
Co Principle Investigator for Alliance for Clinical Trails in Oncology, University of Iowa, Houston, Texas, 2018 - 2022
Section Chief, Hematology and Oncology, Iowa City, 2018 - 2022
Clinical Assistant Professor, University of Iowa, 2017 - 2022
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Grewal, US, Fei, N, Chandrasekharan, C, Bellizzi, AM, Sethi, S, Gosse, M. Neuroendocrine Tumor-Associated Chromogranin A Tubulopathy. Am J Med 138(6):e109-e110, 2025. e-Pub 2025. PMID: 39732152.
- Borbon, LC, Sherman, SK, Breheny, P, Chandrasekharan, C, Menda, Y, Bushnell, DL, Bellizzi, AM, Ear, PH, O'Dorisio, MS, O’dorisio, T, Dillon, JS, Howe, JR. Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors. Annals of surgical oncology 32(2):1136-1148, 2025. e-Pub 2025. PMID: 39505730.
- Howe, JR, Menda, Y, Chandrasekharan, C, Bellizzi, AM, Quelle, DE, O'Dorisio, MS, Dillon, JS. The University of Iowa Neuroendocrine Tumor Clinic. Endocrine Practice 31(1):4-18, 2025. e-Pub 2025. PMID: 39349242.
- Bodeker, KL, Smith, BJ, Berg, D, Chandrasekharan, C, Sharif, S, Fei, N, Vollstedt, S, Brown, H, Chandler, M, Lorack, A, McMichael, S, Wulfekuhle, J, Wagner, BA, Buettner, GR, Allen, BG, Caster, JM, Dion, B, Kamgar, M, Buatti, JM, Cullen, JJ. A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer. Redox Biology 77, 2024. e-Pub 2024. PMID: 39369582.
- Grewal, US, Loeffler, BT, Paschke, A, Dillon, JS, Chandrasekharan, C. Repeat Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors. Journal of Gastrointestinal Cancer 55(3):1165-1170, 2024. e-Pub 2024. PMID: 38780680.
- Mouser, B, Howe, JR, Atari, O, Dillon, JS, Chandrasekharan, C, Parekh, KR, Bashir, MA. Screening for carcinoid heart disease. International Journal of Cardiology: Cardiovascular Risk and Prevention 22, 2024. e-Pub 2024. PMID: 38911359.
- Poellmann, MJ, Bu, J, Liu, S, Wang, AZ, Seyedin, SN, Chandrasekharan, C, Hong, H, Kim, YS, Caster, JM, Hong, S. Nanotechnology and machine learning enable circulating tumor cells as a reliable biomarker for radiotherapy responses of gastrointestinal cancer patients. Biosensors and Bioelectronics 226, 2023. e-Pub 2023. PMID: 36753988.
- Ziogas, IA, Tasoudis, PT, Borbon, LC, Sherman, SK, Breheny, P, Chandrasekharan, C, Dillon, JS, Bellizzi, AM, Howe, JR. Surgical Management of G3 Gastroenteropancreatic Neuroendocrine Neoplasms. Annals of surgical oncology 30(1):148-160, 2023. e-Pub 2023. PMID: 36227392.
- Borbon, LC, Tran, CG, Sherman, SK, Ear, PH, Chandrasekharan, C, Bellizzi, AM, Dillon, JS, O’dorisio, T, Howe, JR. Is There a Role for Surgical Resection of Grade 3 Neuroendocrine Neoplasms?. Annals of surgical oncology 29(11):6936-6946, 2022. e-Pub 2022. PMID: 35802214.
- Tran, CG, Sherman, SK, Suraju, M, Nayyar, A, Gerke, H, Abiad, RG, Chandrasekharan, C, Ear, PH, O’dorisio, T, Dillon, JS, Bellizzi, AM, Howe, JR. Management of Duodenal Neuroendocrine Tumors. Annals of surgical oncology 29(1):75-84, 2022. e-Pub 2022. PMID: 34515889.
Review Articles
- Tran, CG, Sherman, SK, Chandrasekharan, C, Howe, JR. Surgical Management of Neuroendocrine Tumor Liver Metastases. Hematology/Oncology Clinics of North America 39(1):37-53, 2025. e-Pub 2025. PMID: 39510676.
- Halfdanarson, TR, Mallak, N, Paulson, S, Chandrasekharan, C, Natwa, M, Kendi, AT, Kennecke, HF. Monitoring and Surveillance of Patients with Gastroenteropancreatic Neuroendocrine Tumors Undergoing Radioligand Therapy. Cancers 15(19), 2023. e-Pub 2023. PMID: 37835530.
Other Articles
- Ziogas, IA, Dillon, JS, Chandrasekharan, C, Howe, JR ASO Author Reflections. Annals of surgical oncology 30(1):161-162, 2023. PMID: 36209329.
Patient Reviews
CV information above last modified July 09, 2025